Zelebrudomide (NX-2127) (Compound 28) is an orally active PROTAC deggrader, targeting to Brutons Tyrosine Kinase (Btk). Zelebrudomide inhibits proliferation of BTKC481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). Zelebrudomide catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. Zelebrudomide stimulates T cell activation and increases IL-2 production in primary human T Cells[1][2]. (Pink: BTK ligand 10 (HY-168302), Black: (R)-4-(1-(Pyrrolidin-3-ylmethyl)piperidin-4-yl)aniline (HY-168348), Blue: Thalidomide 5-fluoride (HY-W087383)
Molecular Weight:
719.83
Purity:
99.72
CAS Number:
[2416131-46-7]
Formula:
C39H45N9O5
Target:
Btk,PROTACs
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
